Mutations in bone cells can drive leukemia in neighboring stem cells

Certain DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells, researchers from Winship Cancer Institute, Emory University and Children&#39

Updated on: November 02,2023 5

Mutations in bone cells can drive leukemia in neighboring stem cells

Certain DNA mutations in bone cells that support blood development can drive leukemia formation in nearby blood stem cells, researchers from Winship Cancer Institute, Emory University and Children&#39

Updated on:November 02,2023 5

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Updated on: December 21,2023 11

Discovery suggests new way to target mantle cell lymphoma

byWeill Cornell Medical CollegeThe interaction of two proteins required to regulate expression of key genes in the nucleus of mantle cell lymphoma. The red signals are generated at the interacti

Updated on:December 21,2023 11

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on: October 24,2023 33

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on:October 24,2023 33

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on: October 11,2023 222

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be

Updated on:October 11,2023 222

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on: October 31,2023 19

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on:October 31,2023 19

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on: October 11,2023 261

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest

Updated on:October 11,2023 261

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and

Updated on: October 24,2023 42

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and

Updated on:October 24,2023 42

More Evidence Gene Therapy Might Cure Sickle Cell Disease

By Cara MurezHealthDay ReporterMONDAY, June 12, 2023 (HealthDay News) -- A clinical trial that’s attempting to discover a cure for sickle cell disease has found a new gene therapy to be safe and succe

Updated on: October 12,2023 176

More Evidence Gene Therapy Might Cure Sickle Cell Disease

By Cara MurezHealthDay ReporterMONDAY, June 12, 2023 (HealthDay News) -- A clinical trial that’s attempting to discover a cure for sickle cell disease has found a new gene therapy to be safe and succe

Updated on:October 12,2023 176

Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

byNational Cancer InstituteAge-standardized, delay-adjusted overall cancer incidence rates (2014–2018) and age-standardized overall cancer death rates (2015–2019) are illustrated for all cancer

Updated on: December 19,2023 12

Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

byNational Cancer InstituteAge-standardized, delay-adjusted overall cancer incidence rates (2014–2018) and age-standardized overall cancer death rates (2015–2019) are illustrated for all cancer

Updated on:December 19,2023 12

New research discovers gene mutations linked to prostate cancer

A study led by scientists from the Center for Genetic Epidemiology at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center has made a significant leap in our understanding of

Updated on: October 31,2023 27

New research discovers gene mutations linked to prostate cancer

A study led by scientists from the Center for Genetic Epidemiology at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center has made a significant leap in our understanding of

Updated on:October 31,2023 27

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20, 2023Ashling WahnerEarly lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metas

Updated on: October 10,2023 163

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20, 2023Ashling WahnerEarly lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metas

Updated on:October 10,2023 163

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on: October 10,2023 265

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on:October 10,2023 265